Search
for
Sort by
Research 61–90 of 1000+
- Janus Kinase Inhibitors for Alopecia Areata
- Mild-to-moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective analysis of 32 patients
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Response of alopecia areata of the beard to oral tofacitinib
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata
- Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
- Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients
- Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Topical calcipotriol vs narrowband ultraviolet B in treatment of alopecia areata: a randomized-controlled trial
- Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata
- Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial
- Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Baricitinib for the Treatment of Alopecia Areata
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Dietary Habits in Japanese Patients with Alopecia Areata
- Study on Serum Vitamin D in Alopecia Areata Patients
- An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
- Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- European expert consensus statement on the systemic treatment of alopecia areata
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss